Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Work In Process (2023 - 2025)

Historic Work In Process for Iovance Biotherapeutics (IOVA) over the last 3 years, with Q1 2025 value amounting to $12.1 million.

  • Iovance Biotherapeutics' Work In Process rose 10439.63% to $12.1 million in Q1 2025 from the same period last year, while for Mar 2025 it was $12.1 million, marking a year-over-year increase of 10439.63%. This contributed to the annual value of $8.8 million for FY2024, which is 5246.13% up from last year.
  • According to the latest figures from Q1 2025, Iovance Biotherapeutics' Work In Process is $12.1 million, which was up 10439.63% from $8.8 million recorded in Q4 2024.
  • Iovance Biotherapeutics' 5-year Work In Process high stood at $12.1 million for Q1 2025, and its period low was $4.3 million during Q3 2023.
  • For the 3-year period, Iovance Biotherapeutics' Work In Process averaged around $7.6 million, with its median value being $7.3 million (2023).
  • Per our database at Business Quant, Iovance Biotherapeutics' Work In Process soared by 5246.13% in 2024 and then surged by 10439.63% in 2025.
  • Iovance Biotherapeutics' Work In Process (Quarter) stood at $5.7 million in 2023, then surged by 52.46% to $8.8 million in 2024, then skyrocketed by 37.91% to $12.1 million in 2025.
  • Its Work In Process stands at $12.1 million for Q1 2025, versus $8.8 million for Q4 2024 and $5.9 million for Q1 2024.